Get the Stockscreener App
35.69
1.16%
0.41
Pre-market:
35.00
-0.69
-1.93%
Corcept Therapeutics Inc stock is traded at $35.69, with a volume of 1.08M.
It is up +1.16% in the last 24 hours and down -11.06% over the past month.
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.
See More
Previous Close:
$35.28
Open:
$35.28
24h Volume:
1.08M
Relative Volume:
0.52
Market Cap:
$3.80B
Revenue:
$741.17M
Net Income/Loss:
$104.65M
P/E Ratio:
40.78
EPS:
0.8752
Net Cash Flow:
$162.57M
1W Performance:
-1.46%
1M Performance:
-11.06%
6M Performance:
-48.55%
1Y Performance:
-36.26%
1-Day Range:
$34.93
$36.05
1-Week Range:
$33.99
$36.47
52-Week Range:
$28.66
$117.33
Corcept Therapeutics Inc Stock (CORT) Company Profile
Name
Corcept Therapeutics Inc
Sector
Industry
Phone
650.688.8803
Address
101 REDWOOD SHORES PARKWAY, REDWOOD CITY
Compare CORT vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CORT
Corcept Therapeutics Inc
|
35.69 | 3.75B | 741.17M | 104.65M | 162.57M | 0.8752 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Corcept Therapeutics Inc Stock (CORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-31-25 | Downgrade | Wolfe Research | Peer Perform → Underperform |
| Dec-16-25 | Initiated | UBS | Neutral |
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-06-23 | Upgrade | Truist | Hold → Buy |
| Apr-11-23 | Initiated | SVB Securities | Market Perform |
| Apr-04-23 | Initiated | Piper Sandler | Overweight |
| Feb-15-23 | Downgrade | Jefferies | Buy → Hold |
| Aug-01-22 | Downgrade | Truist | Buy → Hold |
| Jul-27-22 | Upgrade | Jefferies | Hold → Buy |
| Jun-27-22 | Resumed | Canaccord Genuity | Buy |
| Feb-02-22 | Initiated | Canaccord Genuity | Buy |
| Jan-28-22 | Initiated | Truist | Buy |
| Aug-05-20 | Downgrade | Jefferies | Buy → Hold |
| Sep-24-19 | Initiated | Jefferies | Buy |
| Sep-06-19 | Initiated | H.C. Wainwright | Buy |
| Feb-04-19 | Downgrade | B. Riley FBR | Buy → Neutral |
| Aug-10-18 | Reiterated | Stifel | Hold |
| May-31-18 | Downgrade | Stifel | Buy → Hold |
| Mar-09-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Aug-31-17 | Initiated | Stifel | Buy |
| Feb-02-17 | Initiated | Ladenburg Thalmann | Buy |
| Apr-21-15 | Initiated | FBR Capital | Outperform |
| Jan-13-14 | Downgrade | Stifel | Buy → Hold |
| Aug-09-13 | Downgrade | Janney | Buy → Neutral |
| Aug-09-13 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Feb-21-12 | Reiterated | JMP Securities | Mkt Outperform |
| Jan-06-10 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jul-17-08 | Initiated | Rodman & Renshaw | Mkt Outperform |
| Jun-21-07 | Upgrade | Punk, Ziegel & Co | Mkt Perform → Accumulate |
View All
Corcept Therapeutics Inc Stock (CORT) Latest News
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds Investors With Losses In Excess Of $100,000 Of Lead Plaintiff Deadline In Class Action Lawsuit Against Corcept Therapeutics IncorporatedCORT - ChartMill
Corcept Therapeutics Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
Corcept Therapeutics (NASDAQ: CORT) Form 144 lists 20,000-share sale on 03/04/2026 - Stock Titan
CORT SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Stockholders with Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
Law Offices of Frank R. Cruz Encourages Corcept Therapeutics Incorporated (CORT) Shareholders To Inquire About Securities Fraud Class Action - wjfw.com
Lost Money on Corcept Therapeutics Incorporated(CORT)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - PR Newswire
Xeris Biopharma: Undervalued Given The Potential Of Its Drug Portfolio (NASDAQ:XERS) - Seeking Alpha
Corcept Therapeutics faces securities lawsuit over FDA rejection By Investing.com - Investing.com Canada
Corcept Therapeutics Incorporated Securities Fraud Class Action Result of FDA Approval Issues and 50% Stock Decline - GlobeNewswire Inc.
[Form 4] CORCEPT THERAPEUTICS INC Insider Trading Activity - Stock Titan
Corcept (CORT) CEO awarded 460,000 stock options in new grant - Stock Titan
Corcept Therapeutics (CORT) officer awarded stock options on 140,000 shares - Stock Titan
Corcept Therapeutics (CORT) CFO awarded stock options on 140,000 shares - Stock Titan
Corcept Therapeutics (CORT) CSO Hazel Hunt awarded 140,000 stock options - Stock Titan
Corcept (NASDAQ: CORT) grants CBO 140,000 options vesting over four years - Stock Titan
Investors of Corcept Therapeutics, Inc. (CORT) Seeking Recovery - The National Law Review
CORCEPT THERAPEUTICS INCORPORATED (CORT) DEADLINE ALERT Bernstein Liebhard LLP Reminds Corcept Therapeutics Incorporated Investors of Upcoming Deadline - ACCESS Newswire
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); ... - Bluefield Daily Telegraph
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Integer Holdings Corp. (NYSE: ITGR); Kyndryl Holdings (NYSE: KD); and Molina Healthcare, Inc. (NYSE: MOH): Grabar Law Office Investigates Claims on Your Beha - GlobeNewswire
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Integer Holdings Corp. (NYSE: ITGR); Kyndryl Holdings (NYSE: KD); and Molina Healthcare, Inc. (NYSE: MOH): Grabar Law Office Investigates Claims on Your Behalf - GlobeNewswire Inc.
Bronstein, Gewirtz & Grossman LLC Urges Corcept - GlobeNewswire
Hagens Berman Alerts Corcept Therapeutics (CORT) Investors to Securities Class Action and April 21 Lead Plaintiff Deadline - ChartMill
The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of April 21, 2026 in Corcept Therapeutics Incorporated LawsuitCORT - PR Newswire
CORT INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Corcept Therapeutics Incorporated Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A - GlobeNewswire
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit - Financial Times
ARDT IMPORTANT DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Ardent Health, Inc. Investors to Secure Counsel Before Important March 9 Deadline in Securities Class Action - GlobeNewswire Inc.
Shareholders who lost money in shares of Corcept - GlobeNewswire
ROSEN, A LEADING AND RANKED FIRM, Encourages Corcept - GlobeNewswire
FinancialContentDeadline to Lead in Securities Class Action Against Corcept Therapeutics, Inc. (CORT) is April 21, 2026Contact Kaplan Fox - FinancialContent
Deadline Approaching: Corcept Therapeutics Incorporated (CORT) Shareholders Who Lost Money Urged To Contact Law Offices of Howard G. Smith - FinancialContent
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Five9, ... - Bluefield Daily Telegraph
Important Notice to Long-Term Shareholders of Corcept Therapeutics, Inc. (NASDAQ: CORT); Five9, Inc. (NASDAQ - marketscreener.com
CORT Investors Have Opportunity to Lead Corcept Therapeutics Incorporated Securities Fraud Lawsuit with the Schall Law Firm - PR Newswire
Corcept Therapeutics Incorporated (NASDAQ:CORT) Given Average Recommendation of "Hold" by Analysts - MarketBeat
How Relacorilant Setback and Lawsuits Will Impact Corcept Therapeutics’ (CORT) Risk-Reward Profile - simplywall.st
Corcept Therapeutics Accused of Misleading Investors in Class Action - Intellectia AI
Corcept Therapeutics (CORT) Litigation: Hagens Berman - GlobeNewswire
Canaccord Genuity Keeps Their Buy Rating on Corcept Therapeutics (CORT) - The Globe and Mail
Corcept Therapeutics Lawsuits And CRL Put Relacorilant Story Under Pressure - Yahoo Finance
What is Corcept Therapeutics Incorporated’s market positionJuly 2025 Summary & Safe Entry Point Identification - mfd.ru
CORCEPT THERAPEUTICS INCORPORATED (CORT) Stock, Price, News, Quotes, Forecast and Insights - MSN
Is Corcept Therapeutics (CORT) Pricing Reflect Its Sharp One Year Share Price Decline - Yahoo Finance
HC Wainwright Analysts Increase Earnings Estimates for CORT - MarketBeat
TD Asset Management Inc Grows Position in Corcept Therapeutics Incorporated $CORT - MarketBeat
A Look At Corcept Therapeutics (CORT) Valuation After Relacorilant FDA Setback And New Lawsuits - simplywall.st
Corcept Therapeutics v. Teva Pharmaceuticals: Going Outside The Label To Show No Direct Infringement - Mondaq
Portnoy Law Firm Announces Class Action on Behalf of Corcept Therapeutics Incorporated Investors - mydailyrecord.com
Corcept (CORT) director exercises options and moves shares to family trusts - Stock Titan
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Corcept Therapeutics Incorporated of Class Action Lawsuit and Upcoming DeadlinesCORT - PR Newswire
Corcept Therapeutics (NASDAQ: CORT) Investors Who Have Suffered LossesContact Kaplan Fox before April 21, 2026 Lead Plaintiff Deadline - NewMediaWire
Corcept Therapeutics Inc Stock (CORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.11%
6.00%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):